L-Arginine improves endothelial function in renal artery of hypertensive Dahl rats

J Hypertens. 2001 Mar;19(3):421-9. doi: 10.1097/00004872-200103000-00010.

Abstract

Objectives: To clarify whether endothelium-derived contracting factor (EDCF) is developed in renal artery of hypertensive Dahl rats and whether prolonged oral L-arginine treatments prevent development of EDCF and hypertension.

Design: The effect of prolonged salt treatment with or without L-arginine on the renal artery was examined.

Methods and results: Dahl salt-sensitive and -resistant rats were fed a 0.4 or an 8% NaCl diet for 4 weeks. High sodium intake increased arterial pressure in Dahl salt-sensitive rats. The rings of renal arteries were suspended for isometric tension recording. Only in the hypertensive rats, more than 1 micromol/l acetylcholine induced an endothelium-dependent contraction response. The contraction was completely inhibited by indomethacin or ONO-3708 [prostaglandin H2 (PGH2)/thromboxane A2 (TXA2) receptor antagonist], and partially inhibited by OKY-046 (TXA2 synthetase inhibitor). Acetylcholine-induced relaxation was significantly depressed in hypertensive rats, which was partially improved by SQ29548 (PGH2/TXA2 receptor antagonist). Oral L-arginine, but not ONO-8809 (orally active PGH2/TXA2 receptor antagonist) treatment, inhibited the contraction and amended the relaxation. The endothelium-independent contraction to TXA2 receptor agonist U46619 and relaxation to nitroprusside were not altered by L-arginine treatment The L-Arginine treatment reduced blood pressure and sodium retention with increases in urinary NO2-/NO3- and cGMP excretion. Hydralazine treatment also inhibited development of EDCF.

Conclusions: The present results suggest that impaired endothelium-dependent relaxation to acetylcholine is caused in part by induction of EDCF synthesis/release in renal arteries of hypertensive Dahl rats. L-arginine can attenuate sodium retention and development of hypertension, which lead to a decrease in EDCF synthesis in renal arteries.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / pharmacology
  • Acetylcholine / pharmacology
  • Animals
  • Arginine / pharmacology*
  • Blood Pressure / drug effects
  • Bridged Bicyclo Compounds, Heterocyclic
  • Cyclic GMP / urine
  • Endothelins / physiology
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiopathology*
  • Fatty Acids, Unsaturated
  • Hydralazine / pharmacology
  • Hydrazines
  • Hypertension / drug therapy*
  • Hypertension / physiopathology*
  • In Vitro Techniques
  • Indomethacin / pharmacology
  • Male
  • Methacrylates / pharmacology
  • Natriuresis / drug effects
  • Nitrates / urine
  • Nitrites / urine
  • Nitroprusside / pharmacology
  • Rats
  • Rats, Inbred Dahl
  • Renal Artery / drug effects*
  • Renal Artery / physiopathology*
  • Thromboxane A2 / analogs & derivatives*
  • Thromboxane A2 / pharmacology
  • Vasoconstriction / drug effects
  • Vasoconstriction / physiology

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Endothelins
  • Fatty Acids, Unsaturated
  • Hydrazines
  • Methacrylates
  • Nitrates
  • Nitrites
  • Nitroprusside
  • Hydralazine
  • Thromboxane A2
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • SQ 29548
  • ONO 3708
  • Arginine
  • Cyclic GMP
  • ozagrel
  • Acetylcholine
  • Indomethacin